Update on the management of ovarian germ cell tumors

被引:0
作者
Lu, KH [1 ]
Gershenson, DM [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
关键词
ovarian cancer; germ cell tumor; chemotherapy;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Malignant germ cell tumors of the ovary are rare. In-contrast to epithelial ovarian cancer, malign. ant germ cell tumors occur primarily in girls and young women. In addition, with the refinement of chemotherapeutic regimens in the last several decades, overall disease-free survival rates are > 95%. Recent advances have focused on preservation of fertility in the management of patients with these tumors. In a girl or young woman who presents with a pelvic mass, a gynecologist must consider the diagnosis of an ovarian germ cell tumor in the initial workup. Elevated tumor markers may assist in determining the diagnosis preoperatively. Appropriate intraoperative decision making is crucial to adequately treat and stage the cancer without compromising future fertility. For patients with stage I dysgerminoma or stage I low grade immature teratoma, no additional chemotherapy is indicated. However, patients with stage I disease of other germ cell histologies, as well as advanced-stage disease of all germ cell histologies, require adjuvant treatment with bleomycin, etoposide and cisplatin.
引用
收藏
页码:417 / 425
页数:9
相关论文
共 63 条
  • [1] Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin: A Norwegian prospective study
    Albrektsen, G
    Heuch, I
    Kvale, G
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (05) : 767 - 770
  • [2] RANDOMIZED TRIAL OF ETOPOSIDE AND CISPLATIN VERSUS ETOPOSIDE AND CARBOPLATIN IN PATIENTS WITH GOOD-RISK GERM-CELL TUMORS - A MULTIINSTITUTIONAL STUDY
    BAJORIN, DF
    SAROSDY, MF
    PFISTER, DG
    MAZUMDAR, M
    MOTZER, RJ
    SCHER, HI
    GELLER, NL
    FAIR, WR
    HERR, H
    SOGANI, P
    SHEINFELD, J
    RUSSO, P
    VLAMIS, V
    CAREY, R
    VOGELZANG, NJ
    CRAWFORD, ED
    BOSL, GJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 598 - 606
  • [3] Bokemeyer C, 1996, ANN ONCOL, V7, P31
  • [4] Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer
    Bokemeyer, C
    Gerl, A
    Schöffski, P
    Harstrick, A
    Niederle, N
    Beyer, J
    Casper, J
    Schmoll, HJ
    Kanz, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 512 - 516
  • [5] Outcome and reproductive function after chemotherapy for ovarian dysgerminoma
    Brewer, M
    Gershenson, DM
    Herzog, CE
    Mitchell, MF
    Silva, EG
    Wharton, JT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2670 - 2675
  • [6] BROUN ER, 1994, CANCER, V73, P1716, DOI 10.1002/1097-0142(19940315)73:6<1716::AID-CNCR2820730627>3.0.CO
  • [7] 2-L
  • [8] LONG-TERM OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY GERM-CELL TUMORS TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW RESCUE
    BROUN, ER
    NICHOLS, CR
    KNEEBONE, P
    WILLIAMS, SD
    LOEHRER, PJ
    EINHORN, LH
    TRICOT, GJK
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (02) : 124 - 128
  • [9] COMBINATION CISPLATIN, VINBLASTINE, AND BLEOMYCIN CHEMOTHERAPY (PVB) FOR MALIGNANT GERM-CELL TUMORS OF THE OVARY
    CARLSON, RW
    SIKIC, BI
    TURBOW, MM
    BALLON, SC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (10) : 645 - 651
  • [10] Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: A report of the Pediatric Oncology Group and the Children's Cancer Group
    Cushing, B
    Giller, R
    Ablin, A
    Cohen, L
    Cullen, J
    Hawkins, E
    Heifetz, SA
    Krailo, M
    Lauer, SJ
    Marina, N
    Rao, PV
    Rescorla, F
    Vinocur, CD
    Weetman, RM
    Castleberry, RP
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (02) : 353 - 358